Effects of gliclazide on low-density lipoprotein oxidizability and atherosclerosis in cholesterol-fed rabbits.
We studied the effects of a widely-used sulfonylurea, gliclazide, on the oxidizability of low density lipoprotein (LDL) and the development of experimental atherosclerosis in cholesterol-fed rabbits. Daily oral administration of gliclazide (20 mg/kg/day) tended to inhibit the aortic atherosclerosis induced by feeding a 1% cholesterol diet for 10 weeks, although it did not affect diet-induced hyperlipidemia. The administration of gliclazide tended to inhibit the increase of serum thiobarbituric acid-reacting substances (TBARS) by cholesterol feeding and to increase the lag time of the conjugated-diene formation of LDL subjected to in vitro oxidation by copper ion, although without significance. The present study suggests that gliclazide may have antioxidative properties in vivo, and have further beneficial effects for the treatment of diabetes mellitus by inhibiting the oxidation of LDL.
Nomura
H
H
Department of Geriatrics, Nagoya University Graduate School of Medicine, Japan.
Naito
M
M
Kodama
M
M
Kato
Y
Y
Iguchi
A
A
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy*; D001786:Blood Glucose / Q000378:metabolism; D002791:Cholesterol, Dietary / Q000494:pharmacology*; D004435:Eating; D005907:Gliclazide / Q000097:blood / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000097:blood / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010084:Oxidation-Reduction; D011817:Rabbits
D001786:Blood Glucose; D002791:Cholesterol, Dietary; D007004:Hypoglycemic Agents; D008055:Lipids; D008077:Lipoproteins, LDL; D005907:Gliclazide